Voyager Therapeutics (NASDAQ:VYGR) Stock Price Passes Below 50-Day Moving Average – Time to Sell?

Shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR) passed below its fifty day moving average during trading on Friday . The stock has a fifty day moving average of $3.83 and traded as low as $3.43. Voyager Therapeutics shares last traded at $3.50, with a volume of 540,804 shares traded.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on the stock. Wall Street Zen lowered shares of Voyager Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Voyager Therapeutics in a research note on Wednesday, April 15th. Truist Financial raised shares of Voyager Therapeutics to a “strong-buy” rating in a research note on Wednesday, March 25th. Finally, HC Wainwright reaffirmed a “buy” rating on shares of Voyager Therapeutics in a research note on Tuesday, May 26th. One research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $16.50.

Voyager Therapeutics Stock Performance

The stock’s 50 day simple moving average is $3.83 and its two-hundred day simple moving average is $3.94. The firm has a market capitalization of $211.47 million, a PE ratio of -1.78 and a beta of 1.25.

Voyager Therapeutics (NASDAQ:VYGR) last released its earnings results on Thursday, May 7th. The company reported ($0.47) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.54) by $0.07. Voyager Therapeutics had a negative net margin of 319.61% and a negative return on equity of 55.97%. The business had revenue of $1.19 million for the quarter, compared to analyst estimates of $8.79 million. Equities research analysts expect that Voyager Therapeutics, Inc. will post -1.66 earnings per share for the current fiscal year.

Insider Activity

In other news, CEO Alfred Sandrock sold 11,511 shares of the firm’s stock in a transaction that occurred on Thursday, April 2nd. The shares were sold at an average price of $3.87, for a total transaction of $44,547.57. Following the completion of the sale, the chief executive officer owned 472,549 shares in the company, valued at $1,828,764.63. This trade represents a 2.38% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 12.70% of the stock is owned by corporate insiders.

Institutional Trading of Voyager Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. EcoR1 Capital LLC increased its holdings in shares of Voyager Therapeutics by 497.2% during the 4th quarter. EcoR1 Capital LLC now owns 4,002,847 shares of the company’s stock worth $15,731,000 after buying an additional 3,332,544 shares during the last quarter. Vanguard Group Inc. increased its holdings in shares of Voyager Therapeutics by 1.3% during the 3rd quarter. Vanguard Group Inc. now owns 3,250,066 shares of the company’s stock worth $15,178,000 after buying an additional 40,147 shares during the last quarter. Opaleye Management Inc. acquired a new stake in shares of Voyager Therapeutics during the 4th quarter worth approximately $4,704,000. Erste Asset Management GmbH increased its holdings in shares of Voyager Therapeutics by 7.0% during the 4th quarter. Erste Asset Management GmbH now owns 1,195,141 shares of the company’s stock worth $4,718,000 after buying an additional 78,348 shares during the last quarter. Finally, Geode Capital Management LLC increased its holdings in shares of Voyager Therapeutics by 1.1% during the 2nd quarter. Geode Capital Management LLC now owns 1,116,847 shares of the company’s stock worth $3,474,000 after buying an additional 11,929 shares during the last quarter. Institutional investors and hedge funds own 48.03% of the company’s stock.

About Voyager Therapeutics

Voyager Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of gene therapies for serious neurological diseases. The company’s core activities center on the design and delivery of engineered adeno-associated viral (AAV) vectors tailored to target cells in the brain and central nervous system. Through its proprietary CapsidMap and VectorMap platforms, Voyager aims to enhance vector potency, specificity and durability to address diseases with high unmet medical need.

The firm’s pipeline includes several AAV-based candidates in preclinical and early clinical development.